エストラムスチン
分子式: | C23H31Cl2NO3 |
その他の名称: | エストラムスチン、Leo-275、Estramustine、1,3,5(10)-Estratriene-3,17β-diol 3-[bis(2-chloroethyl)carbamate]、1,3,5(10)-Estratriene-3,17β-diol 3-[N,N-bis(2-chloroethyl)carbamate]、Estamustine、エスタムスチン、NSC-89199 |
体系名: | 1,3,5(10)-エストラトリエン-3,17β-ジオール3-[ビス(2-クロロエチル)カルバマート]、1,3,5(10)-エストラトリエン-3,17β-ジオール3-[N,N-ビス(2-クロロエチル)カルバマート] |
エストラムスチン
エストラムスチン
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2023/07/03 14:59 UTC 版)
エストラムスチンリン酸エステル(Estramustine phosphate;EMP)は、男性の前立腺癌の治療に用いられるエストロゲン作用とアルキル化作用の2つの作用を持つ医薬品である[7][5][8][9][10][3][1][11][6][12][13]。細胞増殖抑制作用に関してはエストラムスチンとエストロムスチンのプロドラッグであり、エストロゲン作用に関してはエストラジオールのプロドラッグである[1][3]。1日複数回、経口または静脈内注射で投与される[7][8][3][1][6][12]。日本ではナトリウム塩水和物の経口カプセル剤が承認されている[14]。
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by bz ca cb cc “Pharmacokinetics and pharmacodynamics of estramustine phosphate”. Clin Pharmacokinet 34 (2): 163–72. (February 1998). doi:10.2165/00003088-199834020-00004. PMID 9515186.
- ^ a b c d e “Pharmacology of estrogens and progestogens: influence of different routes of administration”. Climacteric 8 Suppl 1: 3–63. (2005). doi:10.1080/13697130500148875. PMID 16112947 .
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao “Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer”. Int. J. Urol. 8 (2): 33–6. (February 2001). doi:10.1046/j.1442-2042.2001.00254.x. PMID 11240822.
- ^ a b c “Emcyt (estramustine) dosing, indications, interactions, adverse effects, and more”. Medscape Reference. WebMD. 2014年2月8日閲覧。
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y Inoue, Takahiro (2018). “Role of Estramustine Phosphate and Other Estrogens for Castration-Resistant Prostate Cancer”. Hormone Therapy and Castration Resistance of Prostate Cancer. pp. 249–256. doi:10.1007/978-981-10-7013-6_26. ISBN 978-981-10-7012-9
- ^ a b c d e f g h i j k l “Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer”. Drugs Aging 7 (1): 49–74. (July 1995). doi:10.2165/00002512-199507010-00006. PMID 7579781.
- ^ a b c d https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018045s023lbl.pdf
- ^ a b “Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis”. Medicine (Baltimore) 95 (39): e4801. (September 2016). doi:10.1097/MD.0000000000004801. PMC 5265899. PMID 27684806 .
- ^ a b c d e f g h “The use of estramustine phosphate in the modern management of advanced prostate cancer”. BJU Int. 108 (11): 1782–6. (December 2011). doi:10.1111/j.1464-410X.2011.10201.x. PMID 21756277.
- ^ a b c Simpson, D; Wagstaff, AJ (2003). “Estramustine Phosphate Sodium”. American Journal of Cancer 2 (5): 373–390. doi:10.2165/00024669-200302050-00013.
- ^ “Estramustine-based chemotherapy”. Semin. Urol. Oncol. 15 (1): 13–9. (February 1997). PMID 9050135.
- ^ a b c d “Estramustine revisited”. Cancer Treat. Res.. Cancer Treatment and Research 78: 163–84. (1995). doi:10.1007/978-1-4615-2007-8_8. ISBN 978-1-4613-5829-9. PMID 8595142.
- ^ a b c d e f g h Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 540–. ISBN 978-3-642-60107-1
- ^ a b c d e “エストラサイトカプセル156.7mg 添付文書”. www.info.pmda.go.jp. 2022年1月3日閲覧。
- ^ a b c “Androgens and prostate cancer: biology, pathology and hormonal therapy”. Eur. J. Cancer 33 (4): 545–54. (April 1997). doi:10.1016/S0959-8049(96)00444-3. PMID 9274433.
- ^ a b c d e f g Index Nominum 2000: International Drug Directory. Taylor & Francis. (January 2000). pp. 406–407. ISBN 978-3-88763-075-1
- ^ “Estramustine Uses, Side Effects & Warnings”. 2022年1月4日閲覧。
- ^ a b c d e f “Estracyt Capsules - Summary of Product Characteristics (SPC)”. electronic Medicines Compendium. Pfizer Limited (2013年8月12日). 2014年2月8日閲覧。
- ^ Aurel Lupulescu (24 October 1990). Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 40–. ISBN 978-0-8493-5973-6
- ^ a b Valentino Stella; Ronald Borchardt; Michael Hageman; Reza Oliyai, Hans Maag, Jefferson Tilley (12 March 2007). Prodrugs: Challenges and Rewards. Springer Science & Business Media. pp. 174–. ISBN 978-0-387-49782-2
- ^ “The use of estrogen therapy in men”. Curr Opin Pharmacol 3 (6): 650–4. (2003). doi:10.1016/j.coph.2003.07.004. PMID 14644018.
- ^ a b “Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study”. Urology 55 (3): 328–33. (2000). doi:10.1016/s0090-4295(99)00580-4. PMID 10699602.
- ^ “Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy”. Eur. Urol. 27 (3): 192–5. (1995). doi:10.1159/000475159. PMID 7541359.
- ^ “Endocrine treatment of prostate cancer”. J. Steroid Biochem. Mol. Biol. 92 (4): 287–95. (November 2004). doi:10.1016/j.jsbmb.2004.10.005. PMID 15663992.
- ^ “Estrogens in the treatment of prostate cancer”. J. Urol. 154 (6): 1991–8. (December 1995). doi:10.1016/S0022-5347(01)66670-9. PMID 7500443.
- ^ “Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data”. Lancet Oncol. 8 (11): 994–1000. (2007). doi:10.1016/S1470-2045(07)70284-X. PMID 17942366.
- ^ “Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer”. Clin Genitourin Cancer 13 (5): 441–6. (October 2015). doi:10.1016/j.clgc.2015.03.004. PMID 25920994.
- ^ a b c d e f g h i j k l m n “Clinical pharmacokinetics of estramustine phosphate”. Urology 23 (6 Suppl): 22–7. (June 1984). doi:10.1016/S0090-4295(84)80093-X. PMID 6375076.
- ^ a b “Estracyt in advanced carcinoma of the breast: a phase II study”. Clin Radiol 30 (2): 139–47. (March 1979). doi:10.1016/S0009-9260(79)80133-6. PMID 86404.
- ^ a b “Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol”. Br J Urol 55 (4): 408–12. (August 1983). doi:10.1111/j.1464-410X.1983.tb03333.x. PMID 6349745.
- ^ a b c d e f J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 502–503. ISBN 978-1-4757-2085-3
- ^ a b “Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor”. Biochem. Pharmacol. 55 (9): 1427–33. (May 1998). doi:10.1016/S0006-2952(97)00657-6. PMID 10076535.
- ^ a b “Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer”. Acta Urol Belg 58 (4): 89–95. (1990). PMID 2093302.
- ^ a b c “Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients”. J. Urol. 124 (2): 232–6. (August 1980). doi:10.1016/S0022-5347(17)55383-5. PMID 7190620.
- ^ “Recent advances in chemotherapy for advanced prostate cancer”. Curr Urol Rep 1 (1): 48–56. (May 2000). doi:10.1007/s11934-000-0035-z. PMID 12084341.
- ^ a b “The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin”. Br J Urol 58 (4): 412–6. (August 1986). doi:10.1111/j.1464-410X.1986.tb09095.x. PMID 3092893.
- ^ Fredholm, B., Jensen, G., Lindskog, M., & Muntzing, J. (1974, January). Effects of estramustine phosphate (Estracyt) on growth of DMBA-induced mammary tumors in rats. In Acta Pharmacologica et Toxicologica (Vol. 35, pp. 28-28). 35 Norre Sogade, PO Box 2148, DK-1016 Copenhagen, Denmark: Munksgaard Int Publ Ltd.
- ^ a b c “Molecular conformation of estramustine and two analogues”. Mol. Pharmacol. 41 (3): 569–76. (March 1992). PMID 1545778 .
- ^ a b “Estramustine phosphate sodium”. Drug Intell Clin Pharm 18 (5): 368–74. (May 1984). doi:10.1177/106002808401800502. PMID 6373212.
- ^ “Estramustine--a nitrogen mustard/steroid with antimicrotubule activity”. Pharmacol. Ther. 43 (3): 299–319. (1989). doi:10.1016/0163-7258(89)90012-0. PMID 2682681.
- ^ Franco Cavalli; Stan B. Kaye; Heine H Hansen; James O Armitage; Martine Piccart-Gebhart (12 September 2009). Textbook of Medical Oncology, Fourth Edition. CRC Press. pp. 442–. ISBN 978-0-203-09289-7
- ^ “The hydrolysis of estramustine phosphate; in vitro studies”. Eur J Drug Metab Pharmacokinet 8 (4): 395–402. (1983). doi:10.1007/BF03188772. PMID 6673977.
- ^ a b “Single nucleotide polymorphisms of 17beta-hydroxysteroid dehydrogenase type 7 gene: mechanism of estramustine-related adverse reactions?”. Int. J. Urol. 16 (10): 836–41. (October 2009). doi:10.1111/j.1442-2042.2009.02374.x. PMID 19735314.
- ^ a b “Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients”. Int. J. Urol. 12 (2): 166–72. (February 2005). doi:10.1111/j.1442-2042.2005.01004.x. PMID 15733111.
- ^ Gate, Laurent; Tew, Kenneth D. (2011). “Alkylating Agents”. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. pp. 61–85. doi:10.1007/978-90-481-9704-0_4. ISBN 978-90-481-9703-3
- ^ http://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf
- ^ Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 245, 454. ISBN 978-3-7692-2114-5
- ^ Thorsteinn Loftsson (25 January 2014). Drug Stability for Pharmaceutical Scientists. Academic Press. pp. 77–. ISBN 978-0-12-411562-0
- ^ S. Bernal (21 August 1997). Drug Resistance in Oncology. CRC Press. pp. 287–. ISBN 978-1-4200-0209-6
- ^ Samuel J. Murff (20 February 2012). Safety and Health Handbook for Cytotoxic Drugs. Government Institutes. pp. 89–. ISBN 978-1-60590-705-5
- ^ William D. Figg; Cindy H. Chau; Eric J. Small (14 September 2010). Drug Management of Prostate Cancer. Springer Science & Business Media. pp. 402–. ISBN 978-1-60327-829-4
- ^ “エストラサイトカプセル156.7mg インタビューフォーム”. www.info.pmda.go.jp. 2022年1月6日閲覧。
エストラムスチンと同じ種類の言葉
ムスチンに関連する言葉 | エストラムスチン(えすとらむすちん) セムスチン(せむすちん) カルムスチン(かるむすちん) フォテムスチン(ふぉてむすちん) 塩酸ベンダムスチン(えんさんべんだむすちん) |
- エストラムスチンのページへのリンク